Researchers from Peking University Cancer Hospital and Institute Describe Findings in B-Cell Lymphoma (Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm,...).

A recent study conducted by researchers from Peking University Cancer Hospital and Institute in China has found that loncastuximab tesirine (Lonca) shows promise as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study involved 64 Chinese patients who had failed two lines of systemic therapies and were treated with Lonca. The overall response rate (ORR) was 51.6%, with a complete response rate of 23.4%. The treatment was well-tolerated, although some patients experienced hematological events and other adverse events. The results of this study are consistent with a previous study conducted on white patients. [Extracted from the article]